{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:27:56Z","timestamp":1760711276731},"reference-count":20,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023,12,26]]},"DOI":"10.3960\/jslrt.23040","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T22:12:27Z","timestamp":1703542347000},"page":"246-250","source":"Crossref","is-referenced-by-count":2,"title":["Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease"],"prefix":"10.3960","volume":"63","author":[{"given":"Hiroki","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Tsuyama Chuo Hospital, Okayama, Japan,"},{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tsuyama Chuo Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Asakura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomofumi","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tsuyama Chuo Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tsuyama Chuo Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Respiratory Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 R\u00f6th A, Fryzek J, Jiang X <i>et al.<\/i> Complement\u2010mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion. 2022; 62: 51-59.","DOI":"10.1111\/trf.16745"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Campo E, Jaffe ES, Cook JR <i>et al.<\/i> The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140: 1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Chapin J, Terry HS, Kleinert D, Laurence J. The role of complement activation in thrombosis and hemolytic anemias. Transfus Apher Sci. 2016; 54: 191-198.","DOI":"10.1016\/j.transci.2016.04.008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Polack FP, Thomas SJ, Kitchin N <i>et al.<\/i> Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383: 2603-2615.","DOI":"10.1056\/NEJMoa2034577"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Baden LR, El Sahly HM, Essink B <i>et al.<\/i> Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384: 403-416.","DOI":"10.1056\/NEJMoa2035389"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Suzuki Y, Shiba T. Chronic cold agglutinin disease after a third COVID-19 mRNA vaccination. Int J Hematol. 2023; 117: 618-621.","DOI":"10.1007\/s12185-022-03480-z"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 P\u00e9rez-Lamas L, Moreno-Jim\u00e9nez G, Tenorio-N\u00fa\u00f1ez MC <i>et al.<\/i> Hemolytic crisis due to Covid\u201019 vaccination in a woman with cold agglutinin disease. Am J Hematol. 2021; 96: E288-E291.","DOI":"10.1002\/ajh.26214"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Fattizzo B, Pasquale R, Bellani V, Barcellini W, Kulasekararaj AG. Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature. Front Immunol. 2021; 12: 791429.","DOI":"10.3389\/fimmu.2021.791429"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 R\u00f6th A, Barcellini W, D\u2019Sa S <i>et al.<\/i> Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021; 384: 1323-1334.","DOI":"10.1056\/NEJMoa2027760"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 R\u00f6th A, Berentsen S, Barcellini W <i>et al.<\/i> Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022; 140: 980-991.","DOI":"10.1182\/blood.2021014955"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Lazarian G, Quinquenel A, Bellal M <i>et al.<\/i> Autoimmune haemolytic anaemia associated with COVID\u201019 infection. Br J Haematol. 2020; 190: 29-31.","DOI":"10.1111\/bjh.16794"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Angileri F, L\u00e9gar\u00e9 S, Marino Gammazza A <i>et al.<\/i> Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID\u201019? Br J Haematol. 2020; 190: e92-e93.","DOI":"10.1111\/bjh.16883"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nikitin PA, Rose EL, Byun TS, Parry GC, Panicker S. C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro. J Immunol. 2019; 202: 1200-1209.","DOI":"10.4049\/jimmunol.1800998"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kamesaki T, Nishimura J, Wada H <i>et al.<\/i> Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol. 2020; 112: 307-315.","DOI":"10.1007\/s12185-020-02899-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013; 122: 1114-1121.","DOI":"10.1182\/blood-2013-02-474437"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Berentsen S, Ulvestad E, Gjertsen BT <i>et al.<\/i> Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103: 2925-2928.","DOI":"10.1182\/blood-2003-10-3597"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ikeda D, Terao T, Fukumoto A <i>et al.<\/i> Antibody status following booster vaccination against SARS\u2010CoV \u20102 virus in patients with haematologic malignancies. Br J Haematol. 2023; 200: 568-572.","DOI":"10.1111\/bjh.18549"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Broome CM. Complement-directed therapy for cold agglutinin disease: sutimlimab. Expert Rev Hematol. 2023; 16: 479-494.","DOI":"10.1080\/17474086.2023.2218611"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Bartko J, Schoergenhofer C, Schwameis M <i>et al.<\/i> A Randomized, First\u2010in\u2010Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. Clin Pharmacol Ther. 2018; 104: 655-663.","DOI":"10.1002\/cpt.1111"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Berentsen S, Barcellini W, D\u2019Sa S, Jilma B. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy. 2022; 14: 1191-1204.","DOI":"10.2217\/imt-2022-0085"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23040\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:17:52Z","timestamp":1715577472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23040\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23040","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"article-number":"23040"}}